In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Caladrius Biosciences, Inc.. Trade Record

NASDAQ:CLBS Caladrius Biosciences, Inc. stock gains 41.57% Exit Feb 16, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CLBS Jan 24, 2017, priceSeries
About Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc. provides development and manufacturing services to the cell therapy industry in the United States. The company offers process development and clinical manufacturing services for therapeutic candidates in various stages of development. It is also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. Caladrius Biosciences, Inc. has a strategic collaboration with Hitachi Chemical Co. America, Ltd. and Hitachi Chemical Co., Ltd. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.

Trade Information
Trade Type
LONG
ReliabilityScore™
88.79
Entry Date
Jan 24, 2017
Entry Price
3.67
Sell Date
Feb 16, 2017
Sell Price
5.20
Net Gain
41.57%
Hold Time
17 Trading Days